Fluss Joel, Geary Denis, deVeber Gabrielle
Division of Pediatric Neurology, The Hospital for Sick Children, Toronto, ON, Canada.
Eur J Pediatr. 2006 Oct;165(10):709-16. doi: 10.1007/s00431-006-0147-7. Epub 2006 May 12.
Nephrotic children are prone to develop thromboembolic complications secondary to an acquired hypercoagulable state. Cerebral sinovenous thrombosis (CSVT) is increasingly recognised in this population, but clinical characteristics and outcome are not well documented.
The database of the Canadian Pediatric Ischemic Stroke Registry (Toronto Site) containing prospectively enrolled children from 1992-2004 with CSVT identified four children with NS. A pooled literature analysis retrieved 17 additional cases reports.
CSVT presented in the majority of cases during the first flare or within 6 months after the onset of NS and was found to occur more often in SSNS/SDNS (n=13) than in SRNS (n=4). Clinical manifestations were non-specific and consisted primarily of seizures (n=8) and signs of raised intracranial pressure (n=16). Imaging studies revealed a predilection for superior sagittal sinus involvement (n=21) and rare parenchymal lesions (n=4). The most consistent biological risk factors were a severe hypoalbuminaemia (n=14) and, to a lesser extent, decreased antithrombin (AT) levels (n=9/16). Deficiency of other coagulation inhibitors (protein S, protein C) was not identified. Inherited thrombophilia was documented in a single case, suggesting that acquired, more than genetic, coagulation factors are involved. Anticoagulation was safe, and the outcome was good in most patients, and no recurrence of thrombotic event was reported.
In conclusion, CSVT is now a well-described complication of NS with potential morbidity. A high index of suspicion is required, especially in young children with NS presenting neurological symptoms. Reliable biological predictors of CSVT are lacking.
肾病综合征患儿由于获得性高凝状态,容易发生血栓栓塞并发症。脑静脉窦血栓形成(CSVT)在这一人群中越来越受到关注,但临床特征和预后尚无充分记录。
加拿大儿童缺血性卒中登记处(多伦多站点)的数据库包含1992年至2004年前瞻性纳入的患有CSVT的儿童,从中确定了4例肾病综合征患儿。一项汇总文献分析又检索到17例病例报告。
大多数情况下,CSVT发生在肾病综合征首次发作时或发作后6个月内,且发现其在单纯性肾病综合征/频复发型肾病综合征(SSNS/SDNS,n = 13)中比在激素耐药型肾病综合征(SRNS,n = 4)中更常见。临床表现不具特异性,主要包括癫痫发作(n = 8)和颅内压升高体征(n = 16)。影像学研究显示,上矢状窦受累较为常见(n = 21),实质病变罕见(n = 4)。最一致的生物学危险因素是严重低白蛋白血症(n = 14),其次是抗凝血酶(AT)水平降低(n = 9/16);未发现其他凝血抑制剂(蛋白S、蛋白C)缺乏。仅1例记录有遗传性易栓症,提示获得性而非遗传性凝血因子起主要作用。抗凝治疗安全,大多数患者预后良好,未报告血栓事件复发。
总之,CSVT现在是肾病综合征一种已得到充分描述的并发症,具有潜在的发病率。需要高度怀疑,尤其是对于出现神经症状的肾病综合征幼儿。目前缺乏可靠的CSVT生物学预测指标。